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Most local anesthetics (LAs) are amine compounds bearing one or several phenolic 
rings. Many of them are protonated at physiological pH, but benzocaine (Bzc) is 
permanently uncharged, which is relevant because the effects of LAs on nicotinic 
acetylcholine (ACh) receptors (nAChRs) depend on their presence as uncharged or 
protonated species. The aims of this study were to assess the effects of Bzc on nAChRs 
and to correlate them with its binding to putative interacting sites on this receptor. 
nAChRs from Torpedo electroplaques were microtransplanted to Xenopus oocytes and 
currents elicited by ACh (IAChs), either alone or together with Bzc, were recorded at 
different potentials. Co-application of ACh with increasing concentrations of Bzc 
showed that Bzc reversibly blocked nAChRs. IACh inhibition by Bzc was voltage-
independent, but the IACh rebound elicited when rinsing Bzc suggests an open-channel 
blockade. Besides, ACh and Bzc co-application enhanced nAChR desensitization. 
When Bzc was just pre-applied it also inhibited IACh, by blocking closed (resting) 
nAChRs. This blockade slowed down the kinetics of both the IACh activation and the 
recovery from blockade. The electrophysiological results indicate that Bzc effects on 
nAChRs are similar to those of 2,6-dimethylaniline, an analogue of the hydrophobic 
moiety of lidocaine. Furthermore, docking assays on models of the nAChR revealed 
that Bzc and DMA binding sites on nAChRs overlap fairly well. These results 
demonstrate that Bzc inhibits nAChRs by multiple mechanisms and contribute to better 
understanding both the modulation of nAChRs and how LAs elicit some of their clinical 
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Abbreviations: 
ACh, acetylcholine; ANR, normal Ringer solution with atropine; Bzc, benzocaine; CI, 
confidence interval; DEA, diethylamine; DMA, 2,6-dimethylaniline; EC, extracellular; 
GABAAR, gamma-aminobutyric acid (GABA) receptor type A; IACh, ACh-elicited 
current; IC, intracellular; IGABA, GABA-elicited current; Ip, IACh amplitude at the peak; 
IRb, IACh rebound current; Iss, IACh amplitude at the steady-state; LA, local anesthetic; 
LGIC, ligand-gated ion channel; Lid, lidocaine; MS-222, ethyl 3-aminobenzoate 
methanesulfonate; n, number of oocytes; N, number of oocyte-donor frogs; nAChR, 
nicotinic acetylcholine receptor; RMSD, root-mean-square deviation; SEM, standard 







 Nicotinic acetylcholine receptors (nAChRs) from Torpedo electroplax were 
microtransplanted to the Xenopus oocyte membrane. 
 Benzocaine elicited multiple inhibitory actions on muscle-type nAChRs, 
including open- and closed-channel blockade. 
 Desensitization of nAChRs was boosted by benzocaine. 
 Benzocaine gave raise to marked rebound currents after its co-application with 
acetylcholine. 
 Binding of benzocaine to the nAChR mimicked that of 2,6-dimethylaniline, an 









The main target of local anesthetics (LAs) is the voltage-dependent Na+ channel, 
promoting its blockade and favoring the inactivated state (Hille, 1966; Catterall and 
Mackie, 2001; Fukuda et al., 2005), thus preventing the generation of action potentials 
in nerve cells. Besides, most LAs interact with other ion channels, including ligand-
gated ion channels (LGIC), as the nicotinic acetylcholine (ACh) receptor (nAChR). 
Therefore, it is of therapeutic relevance to understand the mechanisms by which LAs 
modulate nAChRs and other LGIC, since these interactions might account for some of 
the effects found when LAs are used in the clinical practice.  
The muscle-type nAChRs belong to the “Cys-loop” family of receptors, which are 
involved in fast synaptic transmission. They are densely packed at the postsynaptic 
membranes of both skeletal muscle fibers and electrocytes of some electric fishes, as 
Torpedo. These nAChRs are pentameric ensembles composed of 2α1, 1β1, 1δ and either 
1ε or 1γ subunits, assembled to shape a central channel pore. The ε-subunit is present in 
nAChRs located at the neuromuscular junction during the postnatal life (junctional-type 
receptors) and is equivalent to the γ-subunit from Torpedo nAChRs; however, 
embryonic and extrajunctional nAChRs from muscle fibers express a different γ-subunit 
(extrajunctional-type receptors) (Albuquerque et al., 2009; Sine, 2012; Bouzat and 
Mukhtasimova, 2018). Neuronal nAChRs are also pentameric, but they show a larger 
heterogeneity in subunit composition and stoichiometry, despite they only express α (α2- 
α10) and β (β2- β4) subunits (Albuquerque et al., 2009, Hurst et al., 2013). This large 
diversity of nAChR structural conformation is of great relevance since it accounts for a 
plethora of functional and pharmacological properties of nAChRs. The structural 
conformation of muscle-type nAChRs has been mainly unraveled thanks to the 
pioneering work of Nigel Unwin, who used high-resolution electron microscopy on 2-D 
crystals of Torpedo electroplax membranes to determine the nAChR structure in the 
closed (Toyoshima and Unwin, 1988; Unwin, 2005) and open (Unwin, 1995; Unwin 
and Fujiyoshi, 2012) states. The resulting structural models have paved the way to carry 
out “in silico” studies addressed to improve the knowledge, at a molecular scale, of 
nAChR function and modulation. Recently, Newcombe et al. (2018) found some 
inaccuracies in the transmembrane domain (TMD) alignment of the Torpedo nAChR 
structure, mainly involving a shift of one helix turn at the base of the M1-M2 helices 




From the last few decades, it is well known that some LAs modulate nAChR function at 
the end-plate (Steinbach, 1968; Kordas, 1970; Deguchi and Narahashi, 1971; Katz and 
Miledi, 1975). Later on, it was found that certain LAs, or their derivatives with 
positively-charged quaternary-ammonium groups, bind into the nAChR channel pore, 
eliciting open-channel blockade, as referred for the lidocaine (Lid) derivatives QX-222 
and QX-314 (Neher and Steinbach, 1978; Pascual and Karlin, 1998), procaine (Adams, 
1977), Lid (Alberola-Die et al., 2011), diethylamine (DEA), which resembles the 
hydrophilic moiety of Lid (Alberola-Die et al., 2016a) or tetracaine (Ttc; Cobo et al., 
2018). Nevertheless, most LAs are amphipathic molecules, containing an aromatic ring 
and an amine group and, therefore, at physiological solutions, most of them are present 
both as charged and uncharged forms. Hence, most LAs are able to bind to different 
nAChR residues, mainly located at the extracellular- and transmembrane-domains (ECD 
and TMD, respectively), as we have previously reported for Lid (Alberola-Die el al., 
2016a) and Ttc (Cobo et al., 2018). Actually, this heterogeneity in nAChR binding sites 
for Lid, and other LAs, accounts for their multiple inhibitory actions on these receptors 
(Alberola-Die et al. 2011). Furthermore, most Lid actions could be fairly well mimicked 
by small molecules resembling either its hydrophilic fraction, as the positively charged 
DEA (Alberola-Die et al., 2016a), or its hydrophobic moiety, as the uncharged 2,6-
dimethylaniline (DMA, Alberola-Die et al., 2016b). Though most LAs, or their 
derivatives, seem to act on nAChRs by similar blocking mechanisms, as open-channel 
blockers, there are pronounced differences in their potency as nAChR inhibitors, 
differing in several orders of magnitude. Moreover, some LAs show additional effects 
on nAChRs, as the blockade of resting nAChRs, elicited by either Lid (Alberola-Die et 
al., 2011) or Ttc (Middleton et al., 1999; Cobo et al., 2018), or the enhancement of 
desensitization, caused by adiphenine (Spitzmaul et al., 2009), Lid (Alberola-Die et al., 
2011) or Ttc (Cobo et al, 2018). Noticeably, these later effects of LAs on nAChRs are 
usually elicited at concentrations higher than those required to cause the open-channel 
blockade. 
Benzocaine (Bzc) is a hydrophobic LA widely used in clinical practice, mainly to 
relieve mild dental and dermatological pain (González-Rodríguez et al., 2013). As well 
as for other LAs, the main target of Bzc are voltage-gated Na+ channels, but it includes 
also other membrane proteins, including Torpedo nAChRs (Mantipragada et al., 2003) 
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or the Ca-ATPase of the sarcoplasmic reticulum (Di Croce et al., 2015), and thus 
modifies their function. We have now studied the structural and functional interaction of 
Bzc (see chemical structure in the inset to Fig. 1B) on muscle-type nAChRs. The pka of 
Bzc is 2.78 (data from Chemicalize, https://chemicalize.com/) and, therefore, less than 1 
in 10.000 molecules of Bzc are in a charged form at the recording pH. Interestingly, in 
spite of being an uncharged molecule, it has been reported that Bzc elicits voltage-
independent blockade of nAChRs by acting into the open channel pore (Ogden et al., 
1981). Therefore, the present work was aimed, first, to ascertain the mechanisms by 
which Bzc modulates muscle-type nAChR function and, second, to decipher the nAChR 
sites at which Bzc binds to mediate its actions. Our results confirm that Bzc blocks 
nAChRs by acting within the channel-pore, but also blocks resting nAChRs and 
promotes their desensitization at concentrations close to its IC50. In addition, the 
functional effects of Bzc on nAChRs have been correlated to its binding at specific sites 
on the nAChR, determined by docking assays, using structural models of Torpedo 
nAChR, both in the closed and the open states, as templates. 
Preliminary results of this work have been published elsewhere in an abstract form 
(Cobo et al., 2016). 
 
EXPERIMENTAL PROCEDURES 
Oocyte microinjection with proteoliposomes bearing either nAChRs or GABAARs 
Torpedo marmorata nAChRs were purified and reconstituted in asolectin lipids, at a 
final protein concentration of 0.3-1.2 mg/mL, as previously reported (Ivorra et al., 
2002). Adult female Xenopus laevis (purchased from Centre National de la Recherche 
Scientifique, Montpellier, France) were immersed in cold 0.17% tricaine 
methanesulfonate (MS-222) for 20 min and a piece of ovary was drawn out aseptically. 
Animal handling was carried out in accordance with the guidelines for the care and use 
of experimental animals adopted by the European Union (European Communities 
Council Directive of 24 November 1986, 86/609/EEC), and the animal protocol was 
approved by the Ethic Committee of Universidad de Alicante. Stage V and VI oocytes 
were isolated and their surrounding layers removed manually. Cells were kept at 15-
16ºC in a modified Barth’s solution (88 mM NaCl, 1 mM KCl, 2.40 mM NaHCO3, 0.33 
mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 mM HEPES (pH 7.4), 100 U/mL 
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penicillin and 0.1 mg/mL streptomycin) until used. Oocytes were microinjected with 
100 nL of an aliquot of reconstituted nAChRs (Morales et al., 1995). 
In some experiments, gamma-aminobutyric acid (GABA) receptors (GABAARs) were 
microtransplanted to the Xenopus oocyte membrane from rat-brain synaptosomal-
enriched membranes, as previously described (Alberola-Die et al., 2016a). Briefly, 
whole rat brains were removed and homogenized in a glass-Teflon homogenizer in 10 
volumes of ice-cold 10 mM Tris-citrate buffer (pH 7.4) containing 300 mM sucrose, 1 
mM EDTA, 1 mM EGTA and 500 μM PMSF. Each homogenate was spun at 1000 × g 
for 10 min and the supernatant centrifuged at 45,000 × g for 30 min (4°C). Pellet was 
resuspended in 5 mL of 50 mM Tris-citrate (pH 7.4) containing 1 mM EDTA and 1 mM 
EGTA and 500 μM PMSF, frozen in liquid N2 for 5 min and then thawed for 20 min at 
20°C in an ultrasonic bath. Suspension was spun 30 min (4°C) at 45,000 × g. The final 
pellet was resuspended in 50 mM Tris-citrate buffer in 1:10 mass/volume ratio and 
protein concentration assayed (Pierce kit, Pierce Chem. Co., Rockford, IL, USA). 
Samples containing 1-3 mg/mL of protein were aliquoted and kept at -80ºC for later 
use. 
Two-electrode voltage-clamp recordings in oocytes 
Membrane current recordings were performed at 21-25 ºC, 16-72 h after proteoliposome 
injection, as previously reported (Morales et al., 1995; Alberola-Die et al., 2016b). 
Briefly, oocytes were placed in a 150 μL recording chamber and continuously 
superfused with normal frog Ringer’s solution (115 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2, 5 mM HEPES, pH 7.0) supplemented with 0.5 μM atropine sulfate (normal 
Ringer with atropine, ANR) to block any muscarinic response (Kusano et al., 1982). 
The membrane potential was held at -60 mV, unless otherwise stated. Oocytes were 
superfused with ACh either alone or together with Bzc at a flow rate of 13-17 mL/min. 
Membrane currents elicited by ACh (IACh) either alone or co-applied with Bzc, were 
low-pass filtered at 30-1000 Hz and, after sampling at fivefold the filter frequency 
(Digidata series 1440A and 1550; Axon Instruments, Foster City, CA, USA), recorded 
on two PC-computers, using the WCP v. 4.8.6 package developed by J. Dempster 
(Strathclyde Electrophysiology Software, University of Strathclyde, Scotland, UK) and 




Experimental procedures were similar to those used to study the Lid and Ttc effects 
(Alberola-Die et al., 2011; Cobo et al., 2018) on nAChRs. Briefly, Bzc concentration-
IACh inhibition relationship was determined by measuring IAChs evoked by 10 μM ACh 
alone or together with different Bzc concentrations. For competition assays, ACh 
concentration-IACh amplitude curves were obtained by bathing injected oocytes with 
increasing ACh concentrations either alone or together with 500 µM Bzc. IAChs were 
normalized to the maximum IACh evoked by ACh alone or in the presence of Bzc, and 
the values fitted to a sigmoid curve (see equation 4 below). To allow nAChRs to 
recover from desensitization, the interval between consecutive ACh applications was at 
least 5 min. To assess the blockade of resting nAChRs by Bzc, we compared the IAChs 
elicited by ACh (from 3 μM to 1 mM) alone, or co-applied with 500 µM Bzc, either 
directly, or after 12 s of Bzc pre-application (same concentration). In some oocytes, a 20 
s application of Bzc was given during the IACh plateau elicited by either 10 or 100 µM 
ACh, in order to determine the time course of the open-channel blockade by Bzc and the 
recovery from it. To better characterize the rebound currents (IRbs) elicited by Bzc, in 
some experiments, the oocyte remained superfused with Bzc, for 12 s, after withdrawal 
of 100 μM ACh. The voltage-dependence of the IACh blockade by Bzc was assessed by 
applying series of 800 ms voltage pulses (from -120 to +60 mV, in 20 mV steps) to the 
oocyte before ligand superfusion and during the IACh plateau elicited by 10 μM ACh, 
either alone or co-applied with 500 µM Bzc. The -120 mV pulse duration was extended 
up to 1500 ms to allow a more complete current relaxation. 
Oocytes previously injected with synaptosomal membranes bearing GABAAR were 
superfused with 1 mM GABA alone or together with Bzc (500 μM - 1 mM) to assess 
the Bzc effects on GABA elicited currents (IGABA).  
 
Data analysis and statistical procedures 
Inhibition curves were determined by measuring the IACh evoked by 10 μM ACh in the 
presence of different concentrations of Bzc. The IAChs (both at the peak, Ip, and 20 s 
later, Iss) elicited in the presence of Bzc were normalized to the IACh evoked by ACh 
alone. Data were fitted to a logistic curve with the Origin 6.1 software (OriginLab Corp. 
Northampton, MA, U.S.A.), using the following equation (1): 
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𝐼𝐼𝐴𝐴𝐴𝐴ℎ+𝐵𝐵𝐵𝐵𝐵𝐵 = � 
𝐼𝐼𝐴𝐴𝐴𝐴ℎ𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐼𝐼𝐴𝐴𝐴𝐴ℎ𝑚𝑚𝑚𝑚𝑚𝑚
1 +  ([𝐵𝐵𝐵𝐵𝐵𝐵]/𝐼𝐼𝐼𝐼50)𝑛𝑛𝐻𝐻
� +  𝐼𝐼𝐴𝐴𝐴𝐴ℎ𝑚𝑚𝑚𝑚𝑚𝑚 
where IACh+Bzc is the IACh amplitude elicited by co-application of 10 μM ACh with Bzc at 
a given concentration ([Bzc]); IAChmax and IAChmin are the maximum and minimum 
IAChs recorded, respectively; IC50 is the Bzc concentration required to inhibit half the 
IAChmax; and nH is the Hill coefficient. 
The rate of desensitization (IACh decay) was determined by measuring the IACh amplitude 
elicited by 100 µM ACh, either alone or co-applied with 500 µM Bzc, at different times 
after Ip. Desensitization rates were computed using the equation (2): 
 
𝐷𝐷𝑡𝑡𝑡𝑡 = [1 − (𝐼𝐼𝑡𝑡𝑡𝑡 𝐼𝐼𝑝𝑝)⁄ ] × 100 
where Dti is the desensitization value at 2, 10 or 20 s after Ip; and Iti the remaining IACh 
after the specified times (Olivera-Bravo et al., 2007). In addition, based on the methods 
of Sobolevsky et al. (1999), the change in the rate of desensitization induced by 500 µM 
Bzc was determined using the following equation (3): 




where Ip_Ctr and Ip_Bzc are the IACh peaks elicited by ACh either alone or together with 
Bzc, respectively; Iss_Ctr and Iss_Bzc are IAChs 20 s after the corresponding Ips. The 
apparent time-to-peak was determined as the time elapsed from IACh onset to the Ip, from 
currents elicited by ACh either alone or with Bzc. We have called this parameter as 
“apparent” time-to-peak, just to indicate that these values do not necessarily reflect 
“real” time-to-peak values of nAChR activation but those observed in our experimental 
conditions. 
To characterize the pharmacological profile of nAChR blockade by Bzc, nAChRs were 
activated by different concentrations of ACh alone, or co-applied with Bzc, at roughly 
its IC50, either directly, or after its pre-application for 12 s. Dose-response data were 
fitted to the following form of the Hill equation (4): 
𝐼𝐼 𝐼𝐼𝐴𝐴𝐵𝐵ℎ𝑚𝑚𝑚𝑚𝑚𝑚⁄ = [1 + (𝐸𝐸𝐼𝐼50 [𝐴𝐴𝐼𝐼ℎ]⁄ )𝑛𝑛𝐻𝐻]−1 
where I is the IACh amplitude elicited at a given concentration of ACh ([ACh]) applied 
either alone, or together with Bzc; EC50 is the agonist concentration required to obtain 
one-half the maximum IACh; and IAChmax and nH are as in equation 1. 
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Net i/v curves for IACh were obtained by subtracting, for each voltage, the steady-state 
currents attained in ANR (measured during the last 100 ms of the pulse) from the 
corresponding currents recorded in the presence of 10 µM ACh alone or together with 
Bzc. These net IACh values were normalized, for each oocyte, to the ACh response at -60 
mV. 
To determine the rate of open-channel blockade by Bzc, the oocyte was superfused with 
500 µM Bzc at the plateau of the IACh elicited by 10 or 100 µM ACh. Then, the IACh 
decrease elicited by Bzc was fitted to a single exponential function. The time constant 
(τ) of the IACh decay was computed by using the OriginPro 8 software (OriginLab Corp. 
Northampton, MA, U.S.A.). The same procedure was used to determine the kinetics of 
IACh recovery upon Bzc withdrawal. 
Unless otherwise specified, values presented were the mean ± standard error of the 
mean (SEM); “n” indicates the number of oocytes and “N” is the number of oocyte-
donor frogs from which the data were obtained. When comparing two-group means of 
normally distributed values, the Student’s t-test was used; otherwise, the Mann-Whitney 
rank-sum test was applied. Among-group differences were determined by the analysis 
of variance (ANOVA), and mean differences for each pair of groups were determined 
with the Bonferroni t-test. The one-sample t-test was used to compare the mean of an 
experimental group with a specified value. For the comparison of EC50 and IC50 values, 
we used the confidence intervals (CIs) computed by the curve-fitting function of the 
Origin 6.1 software, using 95% confidence levels. The criterion of “non-overlapping 
95% confidence intervals” was used to determine significant differences. A significance 
level of p < 0.05 was considered in all cases. 
 
Virtual docking assays 
Refined nAChR structural model 
As mentioned above, the Torpedo nAChR structures in the open and closed states from 
Unwin models (pdb 4AQ9 and 2BG9, respectively; Unwin 1995, 2005) were recently 
demonstrated inaccurate at the TMD level (Newcombe et al. 2018). These authors 
refined the structural models for the α7 subunit (open and closed states), but not for the 
different subunits conforming the muscle-type nAChR. Therefore, all Torpedo subunits 
have been now modelled by homology using the rectified α7 subunit, both in the open 
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and the closed states. Sequences of Torpedo subunits were obtained from Uniprot 
database (https://www.uniprot.org/) having the codes P02711 (alfa), Q6S3I0 (beta); 
Q6S3H9 (gamma), and Q6S3H8 (delta). Sequence alignments were done with Clustal 
Omega (Sievers et al. 2011) from the European Bioinformatics Institute site 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). The alignments were supervised to ensure 
that all TMDs aligned well with the template. The homology modeling was performed 
using the Swiss-Model Protein Modeling Server (Schwede et al. 2003) on the ExPASy 
Molecular Biology website (http://kr.expasy.org/) under the Project Mode. Structure 
visualization and modifications were made using Yasara v18.11.10 (Krieger et al. 2002) 
and DeepView v4.1 (Guex and Peitsch 1997). The orientation and optimization of the 
side chains were energy minimized using Yasara (http://www.yasara.org). Briefly, this 
process involved an initial short steepest descent minimization to remove bumps, 
followed by a simulated annealing minimization. In this procedure, the simulation cell 
was slowly cooled towards 0º K by downscaling the atom velocities. The entire system 
was subjected to an equilibration process before a short molecular dynamics simulation. 
The equilibration consisted of an initial minimization of the fixed backbone atoms. 
Then, the restrained carbon alpha atoms were minimized and a 10 ps molecular 
dynamics optimization was performed to reduce the initial incorrect contacts and to fill 
the empty cavities. Finally, under periodic boundary conditions in the three coordinate 
directions, the full system was simulated at 310º K for 0.5 ns. All dynamic simulations 
were performed using Yasara (Krieger et al., 2002) with the force field AMBER03 
(Duan et al., 2003). The cutoff used for long-range interactions was set at 10 Å. In 
addition, the model was evaluated using PROCHECK to show the residues in the 
allowed regions of the Ramachandran plots (Laskowski et al., 1996). 
The pentameric organization of the Torpedo nAChR channel was accomplished by 
superposition of the different subunits (either in the open or closed states) on cryo-
electron microscopy structures (pdb 4AQ9 & 2BG9). Yasara was used for 
superimpositions, obtaining a maximum of 4.4 Å of root-mean-square deviation 
(RMSD) over 2708 matched atoms. The final rectified open and closed pentamers of 




Bzc docking assays 
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The structure of Bzc (PubChem CID: 2337) was obtained from the National Center for 
Biotechnology Information (NCBI) PubChem database 
(http://www.ncbi.nlm.nih.gov/pccompound). The docking procedure was as previously 
published (Alberola-Die, et al, 2016a, b; Cobo et al, 2018). Briefly, the global docking 
procedure was accomplished with AutoDock 4 (Morris et al., 2008) implemented in 
Yasara, in which a total of 800 flexible docking runs were set and clustered around the 
putative binding sites. The program then performed a simulated annealing optimization 
of the complexes, which moved the structure to a nearby stable energy minimum, by 
using the implemented Assisted Model Building with Energy Refinement (AMBER03) 
force field (Duan et al., 2003). The Yasara pH command was set to 7.0, to ensure that 
molecules preserved their pH dependency of bond orders and protonation patterns. In 
this way, 99.9% of the Bzc molecules were unprotonated. The best binding energy 
complex in each cluster was stored, analyzed, and used to select the best orientation of 
the interacting partners. 
The theoretical affinities of Bzc at its binding site were determined by calculating the 
binding energy of the ligand-receptor complex. The binding energy was obtained by 
measuring the energy at infinite distance (the unbound state) and subtracting from that 
value the energy of the complex at the bound state.  
Figures were drawn with open source PyMol (The PyMOL Molecular Graphics System, 
Version 1.8 Schrödinger, LLC, at http://www.pymol.org/). 
 
Drugs 
ACh, atropine sulphate, Bzc, GABA, MS-222, DMSO, penicillin and streptomycin 
were from Sigma-Aldrich (St. Louis, MO, USA) and ethanol from Merck KGaA 
(Darmstadt, Germany). HEPES was obtained from Acros Organics (New Jersey, NJ, 
USA). Other reagents of general use were purchased from Scharlau Chemie SA 
(Barcelona, Spain). Bzc solutions were prepared from a 0.1 M stock solution in DMSO 
or, in a few cases, from a 0.5 M stock solution in ethanol. All solutions were made in 





Inhibition of IACh by Bzc 
Superfusion of Bzc (up to 1 mM) to either uninjected oocytes or those bearing 
microtransplanted nAChRs, with the membrane potential held at -60 mV, had almost no 
effects on the cell membrane conductance. Nevertheless, at 300 µM or above, Bzc 
(diluted from a stock solution in either ethanol or DMSO) elicited a small and slow 
outward current in 25 out of 34 cells (74%). This current was most likely due to the 
blockade of native channels of the oocyte membrane, though we did not pursue this 
finding any further. In any case this small outward current (7.2 ± 0.9 nA; n = 25; N = 
12) did not significantly affect the kinetics of the comparatively much larger IAChs 
(usually several hundreds of nA). Thus, for instance, the IACh apparent time-to-peak in 
cells showing Bzc-induced outward current was not significantly different from that of 
oocytes lacking this current. 
In microinjected oocytes, co-application of 10 µM ACh with 0.1 µM-2 mM Bzc 
reversibly reduced Ip, in a dose-dependent manner (Fig. 1A), following a sigmoid 
function (Fig. 1B). Over 300 µM Bzc, the extent of IACh inhibition measured 20 s after Ip 
(Iss) was greater than that corresponding to Ip values. Thus, the IC50 and nH values (see 
equation 1) for the Ip were 382 µM (CI, 305-487 µM; n = 3-20, N = 1-10) and 1.0 ± 0.2, 
respectively (Fig. 1B). The dose-inhibition curve for the Iss showed a lower IC50 (220 
µM, CI 179-251 µM, same cells and donor frogs as above) and a slope 1.2 ± 0.2 (Fig. 
1B). Most likely, this lower IC50 for Iss is because of an enhancement of nAChR 
desensitization by Bzc (see below). 
The specificity of Bzc effects on muscle-type nAChR blockade was assessed by 
comparing its effects on GABAARs, which belong to the same Cys-loop family of 
receptors. When Bzc (500 µM - 1 mM) was co-applied with GABA (1 mM) to oocytes 
microinjected with rat brain synaptosomal membranes bearing GABAARs, IGABA 
decreased and the kinetics of the current decay was accelerated (Fig. 2), as it was found 
for muscle-type nAChRs.  
Voltage-dependence of nAChRs blockade by Bzc 
To unravel whether IACh inhibition exerted by Bzc has voltage-dependence, voltage 
jumps (from -120 to +60 mV, in 20 mV steps) were imposed to oocytes while 
superfusing them with just ANR or during the IACh plateau elicited by 10 µM ACh, 
either alone or together with 500 µM Bzc (Fig. 3A). The i/v curves of net IAChs elicited 
by ACh, either alone or co-applied with 500 µM Bzc, showed that the IACh blockade by 
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Bzc was rather voltage independent (Fig. 3B). Nevertheless, when plotting the 
percentage of IACh inhibition versus membrane potential a slight trend in voltage-
dependence arises. Thus, at negative potentials, the more hyperpolarized the cell 
membrane, the larger IACh blockade (Fig. 3C), though without significant differences at 
the different potentials tested (p > 0.05, ANOVA test). The lack of significant voltage 
dependence of the IACh inhibition by Bzc contrasts with the effects on nAChRs of other 
LAs with more protonatable amine groups on nAChRs, as Lid (Alberola-Die et al., 
2011, 2013) or Ttc (Koblin & Lester, 1979; Cobo et al., 2018). However, this lack of 
voltage-dependence does not exclude that Bzc might bind into the channel pore (see 
below). The i/v curves showed that the IACh reversal potential, close to -5 mV, was not 
affected by the presence of Bzc. 
Competition assays  
To assess the pharmacological profile of nAChR inhibition by Bzc, oocytes were 
superfused with ACh at different concentrations (10, 100 µM and 1 mM) alone or co-
applied with 500 µM Bzc either directly or following a 12 s pre-application of the same 
Bzc concentration. Furthermore, in some cells, 500 µM Bzc was pre-applied for 12 s to 
the oocyte prior to challenging the cell with ACh alone at the referred concentrations. 
Co-application of 10 µM ACh with 500 µM Bzc reduced Ip roughly by half, as expected 
from the IC50 value computed from the dose-inhibition curves (Fig. 1B). Under this 
experimental protocol, the percentage of Ip inhibition was similar for any ACh 
concentration tested, suggesting that Bzc is acting as a non-competitive blocker, except 
for 100 µM ACh, which showed a slightly higher inhibition (56 ± 3 %, n = 18 versus 69 
± 3 %, n = 19 for 10 and 100 µM ACh, respectively; p < 0.05, ANOVA and Bonferroni 
t-test; Fig. 4A1, A2, A3). Interestingly, the Ip blockade increased when 500 µM Bzc was 
pre-applied and then co-applied with ACh. Thus, some of the nAChR blockage elicited 
by this protocol of Bzc application should be due to Bzc binding to resting (closed) 
nAChRs, preventing their activation by the agonist. Furthermore, pre- and co-
application of Bzc slowed down the IACh activation, and so the time needed to reach Ip 
was markedly increased (Table 1; Fig. 4A1, A2, A3). Noticeably, when Bzc was solely 
pre-applied before challenging the cell with ACh alone, i.e. Bzc only acting on resting 
nAChRs, the Ip also decreased and IACh activation slowed down, particularly at high 
ACh concentrations (Table 1 and Fig. 4A1, A2, A3). This suggests that binding of Bzc to 
resting nAChRs disturbs the agonist binding, the channel gating or both events. Given 
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the effects of Bzc pre-application on IACh activation, we quantified its inhibitory action 
on nAChRs only at the Isss, i.e. the IACh amplitudes 20 s after its Ip in the presence of 
Bzc. As shown in Fig. 4B, the extent of Iss inhibition was rather similar if Bzc was just 
co-applied with ACh or pre-applied and then co-applied with ACh. The percentage of Iss 
inhibition when co-applying 10 µM ACh with 500 µM Bzc was close to 80%, and this 
percentage increased significantly with the ACh concentration (Fig. 4B). This 
dependence on ACh concentration might be related to the enhancement of nAChR 
desensitization by Bzc (see below), which increases with ACh concentration. 
Interestingly, at 10 µM ACh, Iss decreased by roughly 25% when Bzc was just pre-
applied, and this inhibitory effect was even more pronounced as the ACh concentration 
augmented. This indicates that Bzc is blocking resting (closed) nAChRs and that its 
recovery after rinsing the Bzc is very slow, particularly at high ACh concentrations 
(Fig. 4B). 
Rebound IAChs elicited by Bzc 
When oocytes bearing nAChRs are challenged with ACh at almost saturating 
concentrations (1 mM), an IRb arises during the agonist washout (Fig. 4A3) because at 
these concentrations the ACh molecules by themselves plug the channel pore, eliciting 
open-channel blockade (Sine and Steinbach, 1984; Legendre et al., 2000; Alberola-Die 
et al., 2016b). Since ACh molecules are positively charged, this open-channel blockade 
is voltage-dependent, being only detected at negative potentials. Interestingly, co-
application of Bzc, at its IC50, with 100 µM ACh gave rise to pronounced IRbs (Fig. 
4A2), whereas 100 µM ACh alone did not. Furthermore, if Bzc concentration was raised 
to 1 mM, IRbs were elicited even at 10 µM ACh (see Fig. 1A), which reminds what we 
previously found when co-applying DMA and ACh (Alberola-Die et al., 2016b). To 
further explore the mechanisms involved in this IRb, oocytes were challenged with 100 
µM ACh either alone or co-applied with 500 µM Bzc while the membrane potential was 
held either at -60 or +40 mV. Then we compared the IRb amplitudes, normalized to their 
preceding Iss values, under two experimental conditions: i) washing out ACh and Bzc; 
and ii) removing ACh while Bzc still bathed the cell for 12 s. As indicated above, when 
IAChs were elicited by ACh alone, the agonist rinse elicited IRb neither at -60 nor at +40 
mV (Fig. 5A1, A2). In contrast, washing ACh and Bzc out, after their co-application, 
evoked pronounced IRbs at both membrane potentials. The easiest explanation for these 
IRbs is the Bzc withdrawal from the channel pore while some ACh molecules are still 
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bound to the orthosteric site, since it has been found that Bzc, at these concentrations, 
binds inside the nAChR channel pore (Odgen et al., 1981). Nevertheless, when ACh 
and Bzc co-application was followed by only ACh removal, i.e. the oocyte remained 
superfused with Bzc, IRbs still rose, both at -60 and at +40 mV. However, these IRbs 
were significantly smaller than those elicited when ACh and Bzc were withdrawn 
simultaneously (Fig. 5B). This is a rather unexpected result, since it suggests that the 
own ACh molecules are somehow contributing to these IRbs. Interestingly, the 
mechanism underlying the IRbs elicited by rinsing ACh alone should be different from 
open channel-blockade, because ACh is positively charged and these IRbs were found 
when holding the membrane potential both at -60 and at +40 mV (Fig. 5A2, B).  
Kinetics of nAChR blockade by Bzc and its recovery.  
As aforementioned, nAChR inhibition by Bzc involves both, open- and closed-channel 
blockade. To better understand how open nAChRs are blocked by Bzc, we tested the 
effect of a 20 s pulse of 500 µM Bzc applied during the Iss elicited by a 50 s pulse of 
either 10 or 100 µM ACh (Fig. 6A1, A2). Co-application of ACh and Bzc evoked a fast 
and large inhibition of Iss, being this blockade slightly higher at 100 µM ACh (Iss 
inhibition of 80 ± 2%, n= 9, and 88 ± 2%, n= 10, for 10 and 100 µM ACh, respectively; 
p < 0.05, t-test). However, the kinetics of this IACh blockade was similar when Bzc was 
co-applied with either 10 or 100 µM ACh. The time constant obtained for the fast 
blockade phase, estimated by fitting the recordings to a single exponential function, was 
roughly 1.5 s, corresponding to the solution exchange kinetics (Fig. 6B; Cobo et al., 
2018). This indicates that the blockade of open nAChRs follows a faster kinetics, which 
we cannot resolve. In contrast, the recovery of nAChRs from Bzc blockade showed a 
slower time-course (Fig. 6B) and its kinetics was not limited by our solution exchange. 
Something similar was found when nAChRs were blocked by other LAs, as Lid 
(Alberola-Die et al., 2011) or Ttc (Cobo et al., 2018). Remarkably, the extent of IACh 
recovery 15 s after washing out Bzc was significantly higher when Bzc was co-applied 
with 100 than with 10 µM ACh (Fig. 6C). The difference in the percentages of IACh 
recovery when testing different ACh concentrations might be related to the different 
percentage of open nAChRs at these two ACh concentrations. In this sense, it should be 
pointed out that the kinetics of IACh recovery from open-channel blockade is much faster 
than after closed-channel blockade, the latter lasting several decades of seconds, as 
evidenced by just Bzc pre-application (see Fig. 4A1, A2, A3).  
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Bzc enhancement of nAChR desensitization  
At concentrations above 300 µM, Bzc accelerates IACh decay, which results in a 
percentage of Iss inhibition higher than that of Ip (Fig. 1A, B). This acceleration of IACh 
decay by Bzc is similar to that previously reported for different LAs bearing either a 
single phenolic ring, as Lid or Ttc (Alberola-Die et al., 2011; Cobo et al., 2018) or two 
rings, as adiphenine (Spitzmaul et al., 2009). In all these cases, it has been proposed to 
be mediated by enhancement of nAChR desensitization.  
The effect of Bzc on IACh decay was assessed by co-applying either 10 or 100 µM ACh 
with 500 µM Bzc (i.e. close to its IC50) both at negative and positive potentials (Fig. 7). 
IAChs declined slower at 10 µM ACh (Fig. 7A1, A2) than at 100 µM ACh (Fig. 7A3, A4), 
because nAChR desensitization is dependent on ACh concentration. Interestingly, Bzc 
accelerated differentially the IACh decays at these two ACh concentrations. Thus, at the 
same Bzc dose, the IACh decay was significantly more accelerated when using the higher 
ACh concentration, both at -60 and at +40 mV (Fig. 7). This Bzc effect is better shown 
when plotting the IACh values at different times after Ip for currents elicited by 10 or 100 
µM ACh either alone or co-applied with 500 µM Bzc at -60 and +40 mV (Fig. 7B1, B2, 
respectively). This sharper acceleration of IACh decay when Bzc was co-applied with 100 
µM ACh strongly suggests that this effect is due to enhancement of nAChR 
desensitization instead of a slow nAChR blockade by Bzc. 
Further evidences pointing out that Bzc boosts nAChR desensitization arise when 
plotting the ratios of Iss versus Ip amplitudes elicited by co-applying 10 µM ACh alone 
or with different Bzc concentrations, which denotes the extent of desensitization 
(Sobolevsky et al., 1999; see equation 3). As shown in Fig. 8, below 300 µM Bzc, the 
quotient Iss to Ip in the presence of Bzc (Iss_Bzc/Ip_Bzc) versus the Iss to Ip ratio in the 
presence of ACh alone (Iss_Ctr/Ip_Ctr) is close to 1. In contrast, above 300 µM Bzc, these 
quotients are significantly smaller than 1 (p < 0.05; one sample t-test). Furthermore, the 
higher Iss inhibition the lower is this quotient (Fig. 8A). Therefore, this plot indicates 
that, up to 300 µM Bzc, there is nAChR blockade without changing IACh decay whereas, 
above 300 µM, Bzc elicits both nAChR blockade and enhancement of nAChR 
desensitization. 
Desensitized nAChRs are characterized by a non-conductive pore while the agonist is 
still bound, because its affinity for the ligand is markedly increased (reviewed in 
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Giniatullin et al., 2005; Keramidas and Lynch, 2013). Thus, to verify that Bzc, at its 
IC50, is actually enhancing nAChR desensitization, we plotted the dose-response curves 
for Ip and Iss in the presence and absence of Bzc, as a gauge of nAChR desensitization 
(Gielen and Corringer, 2018). Since, as previously mentioned, very high concentrations 
of ACh (above 100 µM) elicit open-channel blockade of nAChRs, IAChs elicited by 1 
mM ACh were quite often smaller than those evoked by 100 µM ACh. Therefore, we 
restricted the maximum ACh concentration for these plots to 100 µM ACh. As shown in 
Fig. 8B, the apparent affinity (EC50) of nAChR for ACh was slightly higher for Iss than 
for Ip when IAChs were elicited by just ACh (CIs for the apparent EC50s were 10.6 - 13.2 
µM versus 13.0 - 29.1 µM for Iss and Ip, respectively). When IAChs were elicited in the 
presence of Bzc, the dose-response curves were shifted to the left, being particularly 
pronounced for Iss (CIs for the apparent EC50s were 5.1 - 6.3 µM versus 11.9 - 22.7 µM 
for Iss and Ip, respectively). This indicates a significant increase in the apparent affinity 
of nAChR for ACh in the presence of Bzc and, consequently, a higher desensitization. 
Virtual docking assays 
Bzc and nAChR interactions were studied by using as template new structural models of 
nAChRs in the open and closed states, modifying previous Unwin’s models (see 
Experimental Procedures section). Essentially, the new models correct some 
inaccuracies in the loops connecting M1-M2 helices in both the closed and the open 
states of Torpedo nAChRs. A total of 800 runs were accomplished for each 
conformation. The best solutions combining binding energy and frequency 
corresponded to 102 clusters sites differing less than 5 Å of RMSD for the nAChR in 
the open state and 113 clusters for the closed state. Figure 9 shows that most of these 
clusters were located at the ECD (55 and 58% for open and closed states, respectively) 
and the remaining were sited at the TMD. In both conformations, nAChR-Bzc 
interactions at the ECD mainly involved 2 subunits (59 and 55% for open and closed 
states, respectively), chiefly αγ-γ (sites 1 and 6 of Fig. 9, for open and closed nAChRs, 
respectively) and αδ-δ, (sites 4 and 3 for open and closed states, respectively), close to 
the orthosteric binding site, although some clusters were intrasubunit, involving mainly 
the α subunits. TMD clusters were located at intra- or inter-subunit crevices, involving 1 
or 2 subunits, respectively, with a clear preference for the δ subunit in both states. Thus, 
17% of the total solutions in the open state were located at the β-δ inter-subunit (Fig. 9, 
site 7), whereas the same percentage of solutions were at a δ intra-subunit site in the 
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closed state (Fig. 9, site 9). Other energetically favorable sites for both states involved 
both α subunits. Though our binding assays did not find any Bzc cluster inside the 
channel pore, there were a few solutions with intersubunit binding sites near to the inner 
wall of the pore in the open state. Noticeably, we have found very few solutions of Bzc 
interactions at the M1-M2 loop or at residues close by the M2 helix in these corrected 
models of nAChRs and, furthermore, they showed low binding energies. 
DISCUSSION 
This work is aimed to understand the mechanisms underlying the effects of Bzc on 
nAChRs by using two powerful experimental approaches developed by Ricardo Miledi 
and his group. First, the use of Xenopus oocytes as convenient cells to carry on detailed 
functional studies on nAChRs, and other ion channels, from fresh or frozen tissues of 
different species, including humans (Barnard et al., 1982; Miledi et al., 1989). Second, 
the microtransplantation of fully mature proteins, with their native stoichiometry, to 
oocytes by injecting into these cells either plasma membranes or purified and 
reconstituted proteins (Marsal et al., 1995; Morales et al., 1995; Eusebi et al., 2009). 
The present results confirm that Bzc inhibits muscle-type nAChRs and deepen the 
knowledge on the modulating mechanisms of LAs on nAChRs. Bzc and other LAs 
bearing a single aromatic ring, as Lid, procaine or Ttc (Group I of LAs; Arias, 1999), 
share certain effects on nAChRs, though there are also significant differences among 
them. Thus, Bzc potency as nAChR blocker (IC50s of 220 and 382 µM for Iss and Ip, 
respectively) is lower than those found for Lid (11 - 73 µM; Gentry and Lukas, 2001; 
Wang et al., 2010; Alberola-Die et al., 2011) or procaine (25 - 230 µM; Adams, 1977; 
Koblin and Lester, 1979; Gentry and Lukas, 2001; Wang et al., 2010) and much lower 
than that of Ttc (IC50 in the submicromolar range; Cobo et al., 2018). Besides, nAChR 
blockade by Bzc is voltage independent (Koblin and Lester, 1979; Odgen et al, 1981; 
present data), in contrast to the nAChR blockade by Lid (Alberola-Die et al., 2011), 
procaine (Adams, 1977) or Ttc (Cobo et al., 2018). Nevertheless, Bzc elicits flickering 
of single-channel currents from endplate nAChRs, strongly suggesting that it blocks this 
receptor by acting inside the pore (Odgen et al., 1981). In agreement with this, the joint 
withdrawal of ACh and Bzc elicited IRbs, which might be due to relief from the Bzc 
open-channel blockade, in spite that our docking assays did not show Bzc binding 
inside the channel pore, but near to the inner wall of the pore in the open state. These 
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IRbs were more pronounced when co-applying Bzc, at roughly its IC50, with high ACh 
concentrations (100 µM or 1 mM; see Fig. 4A2, A3), though IRbs could be also evoked at 
lower ACh concentrations (10 µM) when increasing Bzc to 1 mM (Fig. 1A). Notably, 
the IRb was voltage independent, since it was evoked when rinsing ACh and Bzc either 
at -60 or at +40 mV (Fig. 5A1, A2). It has been previously reported that IRbs are elicited 
when molecules acting as open-channel blockers are withdrawn from the pore while 
some ACh molecules are still bound to the orthosteric site (Legendre et al., 2000; Liu et 
al., 2008; Alberola-Die et al., 2016b). Although, the presence of IRb points out that Bzc 
is acting as a conventional open-channel blocker, just plugging the pore, an additional 
mechanism must be considered because it was also found, though smaller, when just 
ACh was rinsed (Fig. 5A1, A2). Since ACh is positively charged, its contribution to the 
IRb by an open-channel blockade can be ruled out, because IRb was still found when 
holding the membrane potential at +40 mV. The small IRbs evoked by rinsing just ACh 
should be triggered by the decrease of ACh concentration, which would allow some 
nAChRs to recover from desensitization. As desensitized nAChRs retain ACh 
molecules bound to the orthosteric sites with high affinity, they might gate the channel 
as the nAChRs leave the desensitized state, giving rise to the IRb. Thus, the enhancement 
of nAChR desensitization by Bzc, both at negative and positive potentials (Fig. 7), 
would favor the rise of IRb when ACh is withdrawn. Furthermore, since higher ACh 
concentration results in larger and faster nAChR desensitization, it would be expected 
that, for the same Bzc concentration, IRb would increase with ACh concentration, as it 
actually occurs. Therefore, IRb could arise from two non-exclusive mechanisms which, 
most likely, act combined: i) open-channel blockade of nAChRs by Bzc and ii) nAChR 
recovery from desensitization, which it is enhanced by Bzc and takes place at both 
negative and positive potentials. 
Besides acting as an open-channel blocker, Bzc interacts with resting (closed) nAChRs, 
as evidenced by the IACh inhibition elicited when Bzc was solely pre-applied (Fig. 4). 
This nAChR inhibition differs from that elicited by plugging the channel pore and it is 
characterized by a slow IACh activation (Fig. 4). Noticeably, Bzc pre-application, either 
alone or followed by ACh and Bzc co-application, slowed down the rate of nAChR 
activation and, consequently the apparent time-to-peak increased (Table 1). In contrast, 
just ACh and Bzc co-application decreased the time-to-peak, most likely because of its 
open-channel blockade and enhancement of desensitization, as reported for BW284c5 
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(Olivera-Bravo et al., 2005). Though we have no direct evidences on the mechanisms 
involved in the slowing down of IACh activation, the virtual docking assays indicates that 
Bzc binds close to the orthosteric binding site on resting nAChRs, which might underlie 
its slow activation. Another characteristic effect of Bzc pre-applications is their long 
lasting inhibition of IACh, which surpassed the subsequent 32 s pulse of ACh (Fig. 4). 
Likewise, a very slow recovery of IACh was also found when resting nAChRs were 
blocked by either Ttc (Cobo et al., 2018) or DMA (A.M. unpublished results).  
Furthermore, Bzc enhanced IACh decay when co-applied with ACh at concentrations 
close to or above its IC50 (Figs. 7, 8), as reported for Lid (Alberola-Die et al., 2011) and 
Ttc (Cobo et al., 2018). In the case of Ttc, the enhancement of nAChR desensitization 
seems due to its binding to M2 residues located inside the channel pore, close by the 
ECD-TMD interphase (Cobo et al., 2018). However, in our docking assays neither Bzc 
nor DMA did show a high affinity for those residues (Fig. 10), in spite that IACh decay 
acceleration by these molecules was mostly found when the channel was already gated 
by ACh. The process of nAChR desensitization is yet poorly understood, though it is 
known that not only residues within the channel pore affect the rate of desensitization, 
since different residues at both the ECD (Yakel, 2010) and the ICD (Giniatullin, 2005; 
Shen, 2005) have been also involved. 
As previously mentioned, Lid actions on nAChRs (Alberola-Die et al., 2011) have been 
dissected by using analogues of both its hydrophilic (DEA) and hydrophobic (DMA) 
moieties. Thus, some Lid actions on this receptor overlapped with those of DEA, 
whereas others matched fairly well those elicited by DMA (Alberola-Die et al., 2016a, 
b). Remarkably, DEA and Ttc are molecules largely protonated at pH 7, but they differ 
widely in their actions on nAChRs. For instance, in contrast to DEA, Ttc markedly 
enhances nAChR desensitization, and the putative binding sites of Ttc and DEA on 
nAChRs, as deduced from virtual docking assays, are fairly different (Alberola-Die et 
al., 2016a; Cobo et al., 2018). However, most of the Bzc effects on nAChRs reported 
above remind those elicited by DMA. Thus, Bzc and DMA share, at least, the following 
effects on nAChRs: i) low blocking potency, with IC50s close to 1 mM; ii) voltage-
independent blockade, though they seem to bind inside the channel pore, eliciting open-
channel blockade; iii) pharmacological profile corresponding to non-competitive 
blockade; iv) marked IRbs during the washout phase, both at negative and positive 
potentials; iv) blockade of resting nAChRs, unraveled by Bzc application before 
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challenging the cell with ACh (pre-application protocol); v) slowed down IACh activation 
in pre-application protocols, particularly when testing high ACh concentrations; vi) 
enhancement of nAChR desensitization; vii) binding sites on the nAChR mainly located 
at the ECD (close to the orthosteric binding site and at the δ subunit) and at the TMD 
(particularly at intra- and inter-subunit crevices in the δ subunit, both in the open and 
closed states); and viii) blockade of GABAARs, decreasing the peak-current amplitude, 
accelerating the IGABA decay and eliciting IRbs. Consequently, since DMA effects on 
muscle-type nAChRs mimic fairly well those elicited by the unprotonated form of Lid, 
it follows that Bzc and uncharged Lid molecules overlap their mechanisms of action on 
nAChRs. Moreover, these mechanisms largely differ from those reported for charged 
LAs, as Ttc (Cobo et al., 2018) or other related molecules, as DEA (Alberola-Die et al., 
2016a). 
In conclusion, this work demonstrates that IACh blockade by Bzc involves different 
mechanisms of nAChR inhibition, which are summarized in Figure 11. These results 
contribute to better understanding either how certain therapeutic molecules, as LAs, 
affect nAChR function and point out the putative binding sites for these molecules at 
the nAChR. These results shed new light on how these molecules elicit some of their 
clinical side effects and even might help in the design of new therapeutic molecules 
acting on this subfamily of LGICs. This is of a great relevance because nAChRs are 
involved in multiple pathological processes, including neurodegenerative diseases, 
nicotine addiction, schizophrenia, certain types of epilepsy, congenital myasthenia, 
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Table 1. Effects of 500 µM Bzc on apparent time-to-Ip 
 
  Apparent time-
to-Ip (s) 
    
Test Oocytes Donors 
      
    Control (10 µM ACh) 6.5 ± 0.5 44 5-7 
ACh + Bzc co-app.    2.8 ± 0.4* 18 8 
Bzc pre-app. 8.1 ± 1.2 11 5 
Bzc pre-app. & ACh + Bzc co-app. 5.6 ± 0.8 15 7 
    Control (100 µM ACh) 2.6 ± 0.1 50 6-7 
ACh + Bzc co-app.    1.4 ± 0.2* 19 7 
Bzc pre-app.   6.7 ± 0.6* 16 7 
Bzc pre-app. & ACh + Bzc co-app.   6.1 ± 0.6* 15 6 
    Control (1000 µM ACh) 1.4 ± 0.1 18 2-4 
ACh + Bzc co-app.    0.7 ± 0.2* 9 4 
Bzc pre-app.  6.8 ± 0.5* 6 2 
Bzc pre-app. & ACh + Bzc co-app.  4.1 ± 0.2* 3 2 
        






Figure 1. Benzocaine (Bzc) inhibition of acetylcholine-elicited currents (IAChs). (A) 
Superimposed IAChs evoked by 10 µM ACh either alone (Ctr) or co-applied with 
different Bzc concentrations, as stated on the right. Note that Bzc, at 300 µM or above, 
accelerates IACh decay. Henceforth, unless otherwise stated, the holding potential was 
˗60 mV, downward deflections represent inward currents and the bars above recordings 
indicate the timing of drug application. (B) Bzc concentration-IACh inhibition 
relationship. IACh amplitudes at their peak (Ip; filled symbols) and at their steady-state 
(Iss, measured 20 s after the peak; opened symbols) elicited in the presence of Bzc were 
normalized to the IACh evoked by ACh alone (Ctr) and plotted against the logarithm of 
Bzc concentration. Solid and dashed lines are sigmoid curves fitted to Ip and Iss data, 
respectively. Error bars indicate SEM. Each point is the average of 3-20 oocytes from 1-





Figure 2. Blockade of GABA elicited currents (IGABA) by Bzc. A. Superimposed IGABAs 
elicited by 1 mM GABA alone (black recording) or together with either 500 µM (red 
trace) or 1 mM (green recording) Bzc in an oocyte previously injected with 
synaptosomal-enriched membranes. Notice that Bzc reduced the IGABA and sped up the 
IGABA decay in a dose-dependent way. B. Column graph showing the percentage of IGABA 
inhibition by 500 µM (red columns) or 1 mM (green bars) Bzc. Notice that, at both 
concentrations of Bzc, IGABA inhibition was larger at the steady-state (Iss, striped 
columns) than at its peak (Ip, filled bars). Asterisks indicate statistically significant 
differences among Ip and Iss inhibition (p < 0.05, paired t-test). The number of oocytes 





Figure 3. Voltage-dependence of nAChR blockade by Bzc. (A) IAChs evoked by 10 µM 
ACh alone (black recording) or in the presence of 500 µM Bzc (red recording) when the 
voltage pulses shown underneath were applied. (B) Net i/v relationship of IAChs elicited 
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by the protocol shown in A. Black symbols are for control IAChs (Ctr), whereas those 
evoked in the presence of 500 µM Bzc (+ 500 µM Bzc) are drawn in red. Net IAChs were 
normalized as their percentage of their control IACh at -60 mV (n=10; N=3). (C) Plot 
showing the IAChs left by 500 µM Bzc (IACh+Bzc), normalized to their control (IACh), 
versus the membrane potential (same cells as in B). The lines show the best linear fit to 
the data at either negative or positive potentials. Despite data at negative potentials 
fitted fairly well to a linear function (r2 = 0.978), the normalized values of remnant IACh 






Figure 4. Bzc effects on ACh concentration-IACh amplitude relationship. IAChs evoked by 
ACh at 10 µM (A1), 100 µM (A2) or 1 mM (A3) alone (black recordings), following a 
pre-application of 500 µM Bzc (green recordings; A1, A2, A3), when co-applied with 
500 µM Bzc (red recordings; A1, A2, A3), or when it was pre- and co-applied with 500 
µM Bzc (blue recordings; A1, A2, A3). Each trace is the average of individual recordings 
(“n” and “N” are those indicated in Table 1) previously normalized to their control IACh, 
at the indicated agonist concentrations. (B) Percentage of Iss inhibition elicited by 500 
µM Bzc when tested, at different ACh concentrations, in solely pre-application (green), 
co-application (red) or pre- and co-application protocols (blue). Asterisks indicate 
significant differences in Iss between protocols, for each ACh concentration (p < 0.05, 
ANOVA test). Pound signs indicate significant differences among Iss inhibition at 10 
µM ACh and other concentrations, for each experimental procedure (p < 0.05, ANOVA 






Figure 5. IACh rebound (IRb) elicited by Bzc. (A1, A2) IAChs evoked by 100 µM ACh 
either alone (black recording and black filled bar above) or co-applied with 500 µM Bzc 
(red and blue recordings and filled bars) are shown as insets. The interval indicated by 
the arrows is shown at an expanded scale. IRbs were elicited, after co-applying ACh and 
Bzc, when rinsing to ANR (alone or with Bzc), as indicated by the open bars above the 
recordings, both at -60 (A1) and at +40 mV (A2). Notice the IRbs were found either when 
rinsing to just ANR (red recordings in A1 and A2) or if Bzc remained in the ANR (blue 
recordings in A1 and A2). In contrast, when IAChs were evoked by just ACh (black 
recordings, A1 and A2), there were not IRbs. (B) Column graph showing normalized IRb 
amplitudes (see Experimental Procedures) when rinsing to ANR (red columns, 48.9 ± 
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5.5% versus 51.4 ± 6.8% at -60 mV and +40 mV, respectively; p > 0.05, t-test) or to 
ANR plus Bzc (blue columns, 28.5 ± 3.4% versus 22.8 ± 4.8% at -60 mV and +40 mV, 
respectively; p > 0.05, t-test). Asterisks indicate significant differences between 
protocols at each holding voltage (p < 0.05, t-test). Number of cells and donor-frogs are 







Figure 6. Effects of Bzc on open-channel nAChRs. (A1, A2) Superimposed IAChs elicited 
by 50 s pulses of 10 (A1) or 100 µM ACh (A2) either alone (black recordings) or 
together with 500 µM Bzc, applied at the time indicated by the red horizontal bar (red 
recordings in A1, A2). Ips were normalized to the same amplitude to facilitate the 
kinetics comparisons. The kinetics of IACh inhibition and its recovery from blockade 
followed exponential functions (green traces in A1, A2). (B) Column graphs showing the 
time constant values (τ) obtained for IACh blockade onset (On, red filled columns) and 
for its recovery (Off, red striped columns). The rates of IACh inhibition onset (1.6 ± 0.1 s, 
for both 10 and 100 µM ACh) were limited by the solution exchange kinetics, but those 
for IACh recovery, after Bzc removal, were not (2.2 ± 0.2 s and 3.0 ± 0.4 s for IAChs 
elicited by 10 and 100 µM ACh, respectively). Asterisk indicates significant differences 
among groups (p < 0.05, ANOVA and Bonferroni t-test). (C) Percentage of IACh 
recovery from blockade, 15 s after Bzc washout, for IAChs elicited by 10 (34.8 ± 2.1%, 
black filled column) or 100 µM ACh (45.0 ± 1.1%, black striped column). Asterisks 
indicate significant differences (p < 0.05, t-test; same number of oocytes and donor-





Figure 7. Bzc accelerates IACh decay. (A) Superimposed IAChs elicited, at -60 mV (A1, 
A3) or +40 mV (A2, A4), by 10 (A1, A2) or 100 µM ACh (A3, A4) either alone (black 
recordings) or with 500 µM Bzc (red recordings). IAChs were scaled to the same Ip 
amplitude to better compare the differences in IACh decay. Insets show the corresponding 
IAChs, before their scaling. (B1, B2) Plots showing desensitization rates (equation 2) 
measured at 2, 10 and 20 s after Ip when the holding potential was at either -60 (B1) or 
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+40 mV (B2). For 10 µM ACh (circles), each point is the average of 18 (N = 10) and 7 
(N = 2) oocytes at -60 and +40 mV, respectively, whereas for 100 µM ACh (triangles) 
the number of cells was 20 (N = 8) and 5 (N = 1) at those potentials, respectively. 
Asterisks indicate significant differences among the percentages of IACh decay in 
presence of Bzc (red symbols) and their control values (black symbols), at the indicated 
times (p < 0.05, paired t-test). Pound signs mean significant differences among the 
percentages of IACh desensitization induced by Bzc when it was co-applied with 10 or 





Figure 8. Enhancement of nAChR desensitization depends on Bzc concentration. (A) 
Relationship between changes in IACh desensitization (see equation 3) and extent of Iss 
inhibition when 10 µM ACh was co-applied with Bzc at the indicated concentrations. 
Holding potential was -60 mV in all cases unless for the open red circle, which was +40 
mV. Asterisks indicate significant differences with control desensitization, represented 
as a discontinuous line (n = 6-17, N = 2-9; p < 0.05, one-sample t-test). (B) ACh 
concentration-IACh amplitude relationship in the presence or absence of 500 µM Bzc. Ip 
(filled circles) and Iss (open circles) elicited by different ACh concentrations either 
alone (black circles; n = 4-11, N = 2-5) or co-applied with 500 µM Bzc (red circles; the 
same cells). Data were normalized to the IACh amplitude elicited by 100 µM ACh at each 
different protocol and fitted to the Hill equation (equation 4; black and red lines). The 
nH values of the fitted curves ranged from 1.92 for the Iss_Ctr to 2.38 for the Ip_Ctr, as 





Figure 9. Putative binding sites of Bzc on nAChR in the closed and open states. (A) The 
main binding sites of Bzc (labelled in cyan) on the refined structure of nAChR in the 
closed state are indicated by numbers in the extracellular (ECD; uppermost, sites 1-6) 
and transmembrane (TMD; bottom, sites 7-9) domains. Top (from the synaptic cleft) 
and side views of the nAChR are shown in the left and in the right of this panel, 
respectively. (B) Major binding sites of Bzc at the ECD (top, sites 1-4) and the TMD 
(bottom, sites 5-7) of open nAChRs in views similar to those in panel A. The inset, in 







Figure 10. Comparison of Bzc and DMA binding sites on the nAChR in the closed and 
open conformations. (A) Side view (in the membrane plane; top) and top view (from the 
synaptic cleft; bottom) of the nAChR in the closed state, showing the most favorable 
binding sites of Bzc (blue) and DMA (pink) on it. Notice the strong overlap of Bzc and 
DMA binding sites. The nAChR structure has been made partially transparent to better 
observe Bzc and DMA molecules. (B) Main Bzc and DMA binding sites on nAChR in 
the open state. Views are similar to those shown in panel A. Note the coincidence of 






Figure 11. Model summarizing the effects of Bzc on nAChRs. This scheme shows the 
main effects of Bzc on IACh amplitude and kinetics when binding to different nAChR 
conformations. Resting nAChR (1) binds ACh and the channel opens (2), being 
followed by nAChR desensitization, as evidenced by the IACh decay, which shows a 
time-course dependent on ACh concentration (3). The presence of Bzc, when the 
nAChR is in the open state, causes open-channel blockade (4) and enhances 
desensitization (5). Bzc acting on resting nAChR leads to closed-channel blockade (6) 
and the subsequent ACh and Bzc co-application results in open- and closed-channel 
blockade (7). Recordings are the same shown in previous figures. Notice that IAChs 
elicited by ACh alone are in black, whereas red recordings indicate that Bzc bathed the 
cell, at the time specified by the red horizontal bar. 
 
